MedTrace Logo

Respiratory Microbiome in COPD and Associated Inmune Response.

NCT03321708 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-10-26

No results posted yet for this study

Summary

Hypothesis:

COPD patients with frequent exacerbations have different pulmonary and systemic immune response than COPD patients without frequent exacerbations and this is related to their microbiome.

Conditions

  • Pulmonary Disease (COPD), Chronic Obstructive

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Oriol Sibila Vidal, PhD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-03-31
Completion
2018-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03321708 on ClinicalTrials.gov